Humane Resources: Funding Restrictions in Rare Rheumatic Diseases
As any rheumatologist knows, most non-medical individuals don’t really know what ‘rheumatology’ is. Not so much of a bad reputation, as no reputation. Relatives and […]
Drugs
Global Genes® to Convene RARE Partnering and Investor Forum to Accelerate Drug Development for Rare Diseases
[Aliso Viejo, CA] May 19, 2017 – Global Genes®, a leading rare disease patient advocacy organization, will host the inaugural RARE Partnering and Investor Forum, […]
We must act as England falls behind on access to rare disease medicines
It is crucial that we develop a bespoke process to evaluate ‘orphan’ medicines if we are to eradicate inequality in the system, says Sebastian Stachowiak […]
A Nuanced Message: Marketing to the Rare Diseases Community
Check traditional marketing strategies at the door, because when it comes to rare diseases they simply don’t apply. Experts say established methods of directing campaigns […]
A New Gene Therapy Cure Just Treated Its First-Ever Patient
Rarefied Cures This March, a child with severe combined immune deficiency (SCID) became the second commercial gene therapy patient ever. The patient started receiving a drug […]
Big Pharma Losing Leverage as Payers Raise Pressure on Price
Consolidation among insurers, pharmacy benefit managers key Drug companies are citing growth by volume instead of price Byline: Jared S. Hopkins and Doni Bloomfield, Bloomberg […]
Pharma warns new NICE rules will delay access to meds
Pharma companies are warning that changes to the way the National Institute for Health & Care Excellence (NICE) and NHS England (NHSE) assess new medicines, […]
Ultra-rare disease drugs: has access in England just got harder?
Story from Andrew McConaghie on PharmaPhorum New rules on market access introduced by NICE from 1 April will affect most new medicines – but gaining […]